<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03714386</url>
  </required_header>
  <id_info>
    <org_study_id>MoTHER HDx</org_study_id>
    <nct_id>NCT03714386</nct_id>
  </id_info>
  <brief_title>Study to Explore Morbimortality in Patients Dialyzed With the Theranova HDx in Comparison to On-Line-Hemodiafiltration</brief_title>
  <official_title>A Multicentre, Open-label, Prospective, Randomized Study to Explore the Morbimortality in Patients Dialyzed With the Theranova HDx in Comparison to On-Line - Hemodiafiltration (Study MoTHER HDx)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Senefro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Senefro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      study to evaluate the safety and efficacy of Expanded Hemodialysis (HDx) compared to
      hemodiafiltration (HDF) in patients with chronic kidney disease in Spain for up to 36 months.

      Approximately 700 patients will be included.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, prospective, 1:1 randomized, parallel-group, study to evaluate the
      safety and efficacy of Expanded Hemodialysis (HDx) compared to hemodiafiltration (HDF) in
      patients with chronic kidney disease in Spain for up to 36 months.

      Stable incident hemodialysis patients from hemodialysis in-hospital units and related
      satellite centers in Spain.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular morbility</measure>
    <time_frame>every 3 months</time_frame>
    <description>Occurring during the first 36 months after recruitment (consequence of dialisys) cardiovascular sintomatology (stroke, Acute Coronary Syndrome, Peripheral Arterial Disease, Ischemic Colitis.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Chronic Kidney Disease Requiring Chronic Dialysis</condition>
  <arm_group>
    <arm_group_label>expanded hemodialysis (HDx)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HDx therapies must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription</description>
  </arm_group>
  <arm_group>
    <arm_group_label>online hemodiafiltration (HDF-OL)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OL-HDF therapies must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>A synthetic high-flux dialyzer will be used for OL-HDF.</intervention_name>
    <description>A synthetic high-flux dialyzer used for OL-HDF must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription</description>
    <arm_group_label>online hemodiafiltration (HDF-OL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>A medium cut-off dialyzer will be used for HDx.</intervention_name>
    <description>A medium cut-off dialyzer used for HDx must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription</description>
    <arm_group_label>expanded hemodialysis (HDx)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  End stage Renal Disease (ESRD) patients

          -  Age&gt; 18 years old

          -  HD therapy three times per week for 3 months at least and a maximum of 24 months.

        Exclusion Criteria:

          -  No informed consent provided

          -  Synthetic membrane allergy

          -  Pregnant, breastfeeding, or planning to become pregnant

          -  Active systemic diseases: liver cirrhosis, malignancy prior to enrollment (except
             basal cell skin or similar) and / or immunosuppressive treatment in the 3 months
             before the recruitment.

          -  Scheduled for living-donor transplantation within the study period

          -  Patients with a significant residual renal function (defined as Urea clearance &gt;2,5
             ml/min.

          -  Currently participating in another interventional clinical study or has participated
             in another interventional clinical study in the last 3 months that may interfere with
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>&gt;18 years</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Perez Garcia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Infanta Leonor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia de Sequera Ortiz, PhD</last_name>
    <phone>+34 911918000</phone>
    <email>psequerao@senefro.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia de Sequera Ortiz, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Rafael Perez Garcia, PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2018</study_first_posted>
  <last_update_submitted>August 1, 2019</last_update_submitted>
  <last_update_submitted_qc>August 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

